Master One Thing - Rapamycin Longevity Series cover image

Brian Kennedy on Rapamycin Master Series | Aging is the biggest risk factor for age-related diseases

Master One Thing - Rapamycin Longevity Series

CHAPTER

Plans for the Rapa Mysen trial and considerations for the study population

Discussion on plans to start the Rapa Mysen trial, which aims to examine a wide range of aging parameters, with a focus on inflammatory markers. The chapter also mentions the potential positive response of older individuals in similar studies.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner